7UBD

Solution NMR structure of 8-residue Rosetta-designed cyclic peptide D8.31 in d6-DMSO with cis/trans switching (A-CC conformation)

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	1D 1H	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
2	2D NOESY	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
3	2D ROESY	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
4	2D TOCSY	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
5	2D DQF-COSY	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
6	2D 1H-13C HSQC-ed	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
7	2D 1H-15N HSQC	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
8	2D 1H-13C HMBC	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600
9	2D 1H-13C HSQC-TOCSY	6 mg/mL peptide, 0.03 % TMS	DMSO	NA	0.0	1 atm	293	Bruker AVANCE III 600

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	600

NMR Refinement
Method	Details	Software
na	This is conformation A (CC) of the same 8-residue cyclic peptide present in the same NMR sample in d6-DMSO. CC conformation has cis MLU-3 and cis MLU-7 and CT conformation has cis MLU-3 and trans MLU-7 (PDB 8CTO)	CYANA

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (medoid)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CYANA	3.98.13	Guntert , Mumenthaler, and Wuthrich
2	peak picking	NMRFAM-SPARKY	1.370	Lee, Tonelli, Markley
3	processing	NMRPipe	10.9	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
4	data analysis	TopSpin	4.0.9	Bruker Biospin
5	data analysis	PdbStat	5.21.6	Tejero, Snyder, Mao, Aramini, Montelione
6	structure calculation	CYANA	3.98.13	Guntert , Mumenthaler, and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.